On April 17, 2014 Kyowa Hakko Kirin reported that KHK and Amgen will terminate their licensing agreement in relation to mogamulizumab (Press release Kyowa Hakko Kirin, APR 17, 2014, View Source [SID:1234500438]).
Under the licensing agreement entered into on March 6, 2008, Amgen was granted exclusive rights to develop and commercialize Kyowa Hakko Kirin’s humanized monoclonal antibody mogamulizumab in all non-oncology indications worldwide, except in Japan, China, Korea and Taiwan.
After entering into the agreement, Amgen conducted clinical trials aimed at patients with asthma. Kyowa Hakko Kirin has completed a Phase 1 clinical trial in healthy Japanese adults, and will determine its future development policy after carefully considering the outcome of the Phase 1 results.